Literature DB >> 18669736

Prediction and prevention of recurrent preeclampsia.

John R Barton1, Baha M Sibai.   

Abstract

Women with a history of previous preeclampsia are at increased risk of preeclampsia and other adverse pregnancy outcomes in subsequent pregnancies. The magnitude of this risk is dependent on gestational age at time of disease onset, severity of disease, and presence or absence of preexisting medical disorders. The objective in the management of these patients is to reduce risk factors by optimizing maternal health before conception and to detect obstetric complications as early as possible. This objective can be achieved by formulating a rational approach that includes preconception evaluation and counseling, early antenatal care, frequent monitoring of maternal and fetal well-being, and timely delivery. First-trimester ultrasound examination is essential for accurate dating and establishing fetal number. Laboratory studies are obtained to assess the function of different organ systems that are likely to be affected by preeclampsia and to establish a baseline for future assessment. Recent studies have confirmed that there is no single biomarker that can be clinically useful for the prediction of recurrent preeclampsia. Combinations of biomarkers and biophysical parameters appear promising, but more data are needed to confirm their use in clinical practice. Supplementation with fish oil, calcium, or vitamin C and E and the use of antihypertensives have been shown to be ineffective in the prevention of recurrent preeclampsia and are not recommended. Supplementation with low-dose aspirin may be offered on an individualized basis. Because women with previous preeclampsia are at increased risk for adverse pregnancy outcomes (preterm delivery, fetal growth restriction, abruptio placentae, and fetal death) in subsequent pregnancies, we recommend more frequent monitoring for signs and symptoms of severe hypertension or preeclampsia than that recommended for normal pregnancy. This monitoring may include more frequent prenatal visits, home blood pressure monitoring, or nursing contacts. For patients with a prior pregnancy complicated by preeclampsia with fetal growth restriction, we recommend serial ultrasound evaluation of fetal growth and amniotic fluid volume. The development of severe gestational hypertension, fetal growth restriction, or recurrent preeclampsia requires maternal hospitalization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669736     DOI: 10.1097/AOG.0b013e3181801d56

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  55 in total

Review 1.  Obesity, insulin resistance, and pregnancy outcome.

Authors:  Patrick M Catalano
Journal:  Reproduction       Date:  2010-05-10       Impact factor: 3.906

2.  Twenty-four-hour ambulatory blood pressure monitor heart rate: a potential marker for gestational hypertension in at-risk women.

Authors:  Corenthian J Booker; William C Dodson; Allen R Kunselman; John T Repke; Richard S Legro
Journal:  Am J Perinatol       Date:  2011-12-06       Impact factor: 1.862

3.  Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor.

Authors:  Kathleen Mayor-Lynn; Tannaz Toloubeydokhti; Amelia C Cruz; Nasser Chegini
Journal:  Reprod Sci       Date:  2010-11-15       Impact factor: 3.060

4.  The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension.

Authors:  Vesna D Garovic
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

5.  Therapy: Low-dose aspirin to reduce the risk of pre-eclampsia?

Authors:  Baha M Sibai
Journal:  Nat Rev Endocrinol       Date:  2014-11-18       Impact factor: 43.330

Review 6.  A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: the Italian study group on kidney and pregnancy.

Authors:  Giorgina Barbara Piccoli; Gianfranca Cabiddu; Santina Castellino; Giuseppe Gernone; Domenico Santoro; Gabriella Moroni; Donatella Spotti; Franca Giacchino; Rossella Attini; Monica Limardo; Stefania Maxia; Antioco Fois; Linda Gammaro; Tullia Todros
Journal:  J Nephrol       Date:  2017-04-22       Impact factor: 3.902

7.  Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension.

Authors:  Line Malha; Cristina P Sison; Geraldine Helseth; Jean E Sealey; Phyllis August
Journal:  Hypertension       Date:  2018-06-25       Impact factor: 10.190

8.  The early developments of preeclampsia drugs.

Authors:  Maged M Costantine; Cande V Ananth
Journal:  Expert Opin Investig Drugs       Date:  2016-06-16       Impact factor: 6.206

9.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

Review 10.  Potential markers of preeclampsia--a review.

Authors:  Simon Grill; Corinne Rusterholz; Rosanna Zanetti-Dällenbach; Sevgi Tercanli; Wolfgang Holzgreve; Sinuhe Hahn; Olav Lapaire
Journal:  Reprod Biol Endocrinol       Date:  2009-07-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.